Phase II Clinical Trial to evaluate the Efficacy and Safety of a combination regimen of MK 5172 with/without MK 8742 and/or Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotypes 2, 4, 5 and 6 Infection

Trial Profile

Phase II Clinical Trial to evaluate the Efficacy and Safety of a combination regimen of MK 5172 with/without MK 8742 and/or Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotypes 2, 4, 5 and 6 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C-SCAPE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Jul 2016 According to a Merck media release, Zepatier (elbasvir/grazoprevir) with or without ribavirin has been approved in the European Union for the treatment of chronic hepatitis C virus genotype 1-4 infections in adults.
    • 28 Jan 2016 According to a Merck & Co. media release, Zepatier (elbasvir and grazoprevir) has received US FDA approval for use in treatment of Chronic Hepatitis C virus genotype 1 or 4 infection in adults. The approval was based on six trials (CTPs - 700243227, 700243234, 700242414, 700243273, 700243158 and 700236483).
    • 08 Apr 2015 Results will be presented at The International Liver Congress 2015, according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top